Agnieszka B. Hes-Maj
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Correction: Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer.
Journal: Prostate cancer and prostatic diseases
Published: December 09, 2025
Austrian tricentric real-life analysis of molecular profiles of metastatic biliary tract cancer patients.
Journal: Frontiers in oncology
Published: January 13, 2023
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer.
Journal: Prostate cancer and prostatic diseases
Published: January 06, 2023
Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial.
Journal: Infectious agents and cancer
Published: July 14, 2022
Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.
Journal: International journal of cancer
Published: December 15, 2021
Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival.
Journal: Advances in therapy
Published: March 07, 2021
The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy.
Journal: Urologic oncology
Published: July 22, 2020
Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
Journal: BJU international
Published: April 15, 2020
Claros System: A Rapid Microfluidics-Based Point-of-Care System for Quantitative Prostate Specific Antigen Analysis from Finger-Stick Blood.
Journal: Advances in therapy
Published: October 06, 2018
Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer.
Journal: BJU international
Published: May 27, 2018
The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer.
Journal: Urologia internationalis
Published: March 12, 2018
Last Updated: 09/26/2026